+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 5Years - 17Years
All Genders
ID06100744

Study of Subcutaneous Risankizumab Compared to Adalimumab for Children With Active Juvenile Psoriatic Arthritis Evaluating Safety, Efficacy, and Drug Behavior

Led by AbbVie · Updated on 2026-09-01

40

Participants Needed

34

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying juvenile psoriatic arthritis jPsA, a condition where the immune system attacks healthy joints causing pain, stiffness, and swelling. This trial evaluates the safety of risankizumab and its effect on disease symptoms in children and adolescents with jPsA. The study compares risankizumab to adalimumab, a treatment already approved for jPsA, aiming to assess improvements and side effects. Participants aged 5 to 17 years with active jPsA will be randomly assigned to receive either risankizumab or adalimumab through subcutaneous injections based on body weight. The study consists of two periods Period 1 lasts 24 weeks where participants receive the assigned treatment. Those who respond will continue the same treatment for an additional 100 weeks in Period 2. After treatment ends, participants receiving risankizumab will have a 140-day safety follow-up, while those on adalimumab will have a 70-day follow-up. During the trial, participants will attend regular hospital or clinic visits for medical assessments, blood tests, monitoring for side effects, and completing questionnaires. Researchers will measure improvements in arthritis symptoms using standardized response criteria and monitor adverse events up to 144 weeks. The study aims to gather detailed information on disease activity, treatment response, and safety over approximately two and a half years.

CONDITIONS

Brief Title

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here